Fertility and Infertility Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
BMC Womens Health. 2022 Sep 12;22(1):373. doi: 10.1186/s12905-022-01955-z.
Considering the presence of sexual dysfunction in patients with polycystic ovary syndrome, our aim was to provide scientific evidence studying effect of oral probiotic on sexual function in patients with PCOS treated with letrozole in an Iranian population.
This study was a double blind randomized clinical trial. Eligible women were allocated to Lactofem plus letrozole (n = 20) or letrozole (n = 20). Folic acid was prescribed to all participants in two groups during the study. In group A, Lactofem capsule was administered daily for the first month. In the second month, letrozole (2.5 mg daily from the third day of the menstrual cycle for 5 days) plus Lactofem capsule same as previous month were prescribed. In group B, letrozole administered 2.5 days from the third day of the menstrual cycle for 5 days in the second month. All questionnaires were completed by patients after the intervention (two months after the start of treatment). The Female Sexual Function Index (FSFI) and Body Image Concern Inventory (BICI) were used to assess sexual function and body satisfaction, respectively.
There is statistically significant increase in chemical pregnancy rate (10% vs. 0%; p = 0.05) and clinical pregnancy (10% vs. 0%; p = 0.05) in Probiotic plus letrozole group compared to letrozole group after intervention. Based on our results, there was a statistically significant difference in each domain and sum score of sexual function of before and after the intervention between group (P < 0.05). Our findings have been shown, after eight weeks, the probiotic plus letrozole group had a significant improvement in the FSFI domains and sum score compared to letrozole alone group. Moreover, there are a significant improvement in mean (IQR) of body image score in probiotic group [30 (4.99) vs. 40 (4.36); P < 0.01].
The results of the current study suggests that eight weeks of administration of probiotic may improve chemical and clinical pregnancy rate, sexual function and body satisfaction in women with PCOS.
考虑到多囊卵巢综合征患者存在性功能障碍，我们的目的是在伊朗人群中提供研究口服益生菌对接受来曲唑治疗的 PCOS 患者性功能影响的科学证据。
这是一项双盲随机临床试验。合格的女性被分配到 Lactofem 加来曲唑组（n=20）或仅来曲唑组（n=20）。两组参与者均在研究期间服用叶酸。在组 A 中，第一个月每天服用 Lactofem 胶囊。第二个月，从月经周期的第三天开始每天服用来曲唑（2.5mg，连续 5 天），并加用与前一个月相同的 Lactofem 胶囊。在组 B 中，第二个月从月经周期的第三天开始，连续 5 天服用来曲唑。所有问卷均在干预后（治疗开始后两个月）由患者填写。使用女性性功能指数（FSFI）和身体形象关注量表（BICI）评估性功能和身体满意度。
与仅接受来曲唑治疗相比，益生菌加来曲唑组的化学妊娠率（10%比 0%；p=0.05）和临床妊娠率（10%比 0%；p=0.05）均有统计学显著增加。根据我们的结果，干预前后组间性功能的各个领域和总分均有统计学显著差异（P<0.05）。我们的研究结果表明，与单独使用来曲唑相比，益生菌加来曲唑组在干预 8 周后，FSFI 各领域和总分均显著改善。此外，益生菌组的身体形象评分均值（IQR）[30（4.99）比 40（4.36）；P<0.01]显著改善。
本研究结果表明，益生菌治疗 8 周可提高多囊卵巢综合征患者的化学妊娠率和临床妊娠率、性功能和身体满意度。
